PALVELLA THERAPEUTICS, INC. 8-K

What Happened Palvella Therapeutics, Inc. (PVLA) announced on January 12, 2026 (Item 8.01) that it posted a corporate presentation to its website that company representatives will use in meetings with investors. The company filed the presentation as Exhibit 99.1 to its Form 8-K, which was signed by CFO Matthew Korenberg.

Key Details

• Filing date: January 12, 2026 (Form 8-K, Item 8.01 and Item 9.01 for exhibits).
• Exhibit: 99.1 — Corporate Presentation of Palvella Therapeutics, Inc., dated January 12, 2026.
• Purpose: Presentation will be used in various investor meetings; copy is posted on the company website and filed with the SEC.
• Form signature: /s/ Matthew Korenberg, Chief Financial Officer.

Why It Matters This 8-K is a disclosure that Palvella is actively communicating with investors and has made its current corporate presentation publicly available. Investors who want the latest company overview, strategic updates, or program summaries can review the posted presentation (Exhibit 99.1) for direct information from management.